1 |
Aghion, P. and P. Howitt. 2005. Growth with Quality-Improving Innovations: An Integrated Framework. In Aghion, P. and S. N. Durlauf. (eds.) Handbook of Economic Growth. vol. 1, part A, Amsterdam: Elsevier. pp. 67-110.
|
2 |
Bertram, M. Y., Lauer, J. A., De Joncheere, K., Edejer, T., Hutubessy, R., Kieny, M. P. and S. R. Hill. 2016. "Cost-Effectiveness Thresholds: Pros and Cons," Bulletin World Health Organization, vol. 94, no. 12, pp. 925-930.
DOI
|
3 |
Bils, M. 2004. Measuring the Growth from Better and Better Goods. NBER Working Paper, no. 10606.
|
4 |
Bresnahan, T. F. and R. J. Gordon. 1996. The Economics of New Goods. Chicago: University of Chicago Press.
|
5 |
Dorsey, E. R., de Roulet, J., Thompson, J. P., Reminick, J. I., Thai, A. White-stellato, Z., Beck, C. A., George, B. P., and H. Moses III. 2010. "Financial Anatomy of Biomedical Research, 2003-2008," Journal of the American Medical Association, vol. 303, no. 2, pp. 137-143.
DOI
|
6 |
Grossman, G. M. and E. Helpman. 1991. Innovation and Growth in the Global Economy. Cambridge: MIT Press.
|
7 |
Hausman, J. 2001. "Mismeasured Variables in Econometric Analysis: Problems from the Right and Problems from the Left," Journal of Economic Perspectives, vol. 15, no. 4, pp. 57-67.
DOI
|
8 |
International Federation of Pharmaceutical Manufacturers & Associations. 2017. The Pharmaceutical Industry and Global Health: Facts and Figures 2017. (accessed January 21, 2020)
|
9 |
Jones, C. I. 1998. Introduction to Economic Growth. New York: W.W. Norton.
|
10 |
Jones, C. I. 2002. "Sources of U.S. Economic Growth in a World of Ideas," American Economic Review, vol. 92, no. 1, pp. 220-239.
DOI
|
11 |
Jovanovic, B. and Y. Yatsenko. 2012. "Investment in Vintage Capital," Journal of Economic Theory, vol. 147, no. 2, pp. 551-569.
DOI
|
12 |
Jung, K.-W., Won, Y.-J., King, H.-J., Lee, E. S. and The Community of Population-Based Regional Cancer Registries. 2018. "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015," Cancer Research and Treatment, vol. 50, no. 2, pp. 303-316.
DOI
|
13 |
Koc, C. 2004. "The Productivity of Health Care and Health Production Functions," Health Economics, vol. 13, no. 8, pp. 739-747.
DOI
|
14 |
Kolata, G. 2019. Surgery for Blocked Arteries Is Often Unwarranted, Researchers Find. New York Times, vol. 169, no. 58,514, Section A, p. 19. (Print November, 17, Online November, 16)
|
15 |
Lichtenberg, F. R. 2009. "Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence from Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003," Health Economics, vol. 18, no. 5, pp. 519-534.
DOI
|
16 |
Lichtenberg, F. R. 2014a. "Has Medical Innovation Reduced Cancer Mortality?" CESifo Economic Studies, vol. 60, no. 1, pp. 135-177.
DOI
|
17 |
Lichtenberg, F. R. 2014b. "The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in France, 2000-2009," Economics and Human Biology, vol. 13, pp. 107-127.
DOI
|
18 |
Lichtenberg, F. R. 2014c. "Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009," Health Policy and Technology, vol. 3, no. 1, pp. 36-58.
DOI
|
19 |
Lichtenberg, F. R. 2014d. "The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010," Journal of Human Capital, vol. 8, no. 4, pp. 432-480.
DOI
|
20 |
Lichtenberg, F. R. 2018. "The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: a Two-Way Fixed-Effects Analysis," Forum for Health Economics & Policy, vol. 21, no. 2. (accessed January 21, 2020)
|
21 |
National Cancer Institute. 2012. Long-Term Trial Results Show No Mortality Benefit from Annual Prostate Cancer Screening. (accessed December 7, 2019)
|
22 |
National Cancer Institute. 2019. Enhancing Drug Discovery and Development. (accessed December 7, 2019)
|
23 |
National Institute for Health and Care Excellence. 2019. The Guidelines Manual: Assessing cost effectiveness. (accessed December 7, 2019)
|
24 |
Nordhaus, W. D. 2005. "Irving Fisher and The Contribution of Improved Longevity to Living Standards," American Journal of Economics and Sociology, vol. 64, no. 1, pp. 367-392.
DOI
|
25 |
Organisation for Economic Co-operation and Development (OECD). 2019a. OECD Health Statistics 2019 Definitions, Sources and Methods Hospital discharges by diagnostic categories. (accessed March 21, 2020)
|
26 |
Organisation for Economic Co-operation and Development (OECD). 2019b. International shortlist for hospital morbidity tabulation. (accessed March 21, 2020)
|
27 |
Organisation for Economic Co-operation and Development (OECD). 2019c. OECD Health Statistics database. (accessed December 7, 2019)
|
28 |
U.S. Department of Veterans Affairs, Health Economics Resource Center. 2019. Budget Impact Analysis. (accessed January 21, 2020)
|
29 |
Sampat, B. and F. R. Lichtenberg. 2011. "What are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation?" Health Affairs, vol. 30, no. 2, pp. 332-339.
DOI
|
30 |
Statistics Korea. 2010. 2009 Life Tables for Korea. (accessed January 21, 2020)
|
31 |
World Health Organization (WHO). 2019. Cause of Death Query online database. (accessed January 21, 2020)
|
32 |
Yang, S., Khang, Y.- H., Harper, S., Davey Smith G., Leon, D. A. and J. Lynch. 2010. "Understanding the rapid increase in life expectancy in South Korea," American Journal of Public Health, vol. 100, no. 5, pp. 896-903.
DOI
|
33 |
Centre National Hospitalier d'Information sur le Medicament. 2019. Theriaque database. (accessed January 21, 2020)
|